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1. Introduction 
Acquired immunodeficiency syndrome (AIDS) evolved into a pandemic in less than a 
decade since the first reports of a new set of symptoms that included severe opportunistic 
infections and unusual neoplasms, particularly Kaposi's sarcoma, in homosexual men [1]. 
Nearly 30 years since the discovery of the causative agent [2, 3], human immunodeficiency 
virus (HIV) cannot still be eradicated, nor is there sight of a safe and effective prophylactic 
vaccine in the horizon. Infection with either virus type invariably leads to AIDS; however, 
the less pathogenic HIV-2 stains have been geographically restricted mainly to West Africa, 
whilst the more virulent HIV-1 strains have spread around the globe causing the AIDS 
pandemic [4]. The worst afflicted region is sub-Saharan Africa, where in a few countries 
more than one in five adults is infected with the virus; at the same time, the epidemic is 
spreading most rapidly in Eastern Europe and Central Asia, where the number of people 
living with HIV increased by 250% between 2001 and 2010 [5]. Worldwide, an estimated 34 
million people, including 3.4 million children, were living with HIV at the end of 2010, 
while the related deaths and new infections were 1.8 and 2.7 million, respectively [5].  
Despite these frightening numbers, which are indicative of a growing epidemic far from the 
UNAIDS vision of zero AIDS-related deaths and zero new infections, considerable progress 
has undoubtedly been noted in basic and clinical research in the field of HIV/AIDS [6]; we 
now understand most aspects of HIV pathogenesis and have identified targets suitable for 
therapeutic intervention. The introduction of combination antiretroviral therapy (ART) in 
1996 revolutionized patient care and brought about a significant reduction in AIDS-related 
morbidity and mortality; HIV infection has been transformed into a chronic condition that is 
generally controllable with lifelong treatment, at least in the developed world where 
treatment is available. At the forefront of current anti-HIV research, CCR5 inhibitors 
represent a novel drug class that broadens the therapeutic options of patients, which are 
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currently limited by chronic toxicities or by the presence of resistance to conventional 
antiretrovirals targeting ever mutating virus-encoded structures.  
This chapter focuses on describing the scientific rationale that led to the development of 
coreceptor inhibitors as a new class of host-targeted antiretroviral agents. This description 
entails a revision of the biology of coreceptor usage during HIV entry into target cells and 
viral tropism during the course of infection. The various approaches undertaken to 
pharmaceutically target the most commonly used coreceptor, CCR5, will then be described, 
with a special focus on small molecule CCR5 inhibitors (also termed “CCR5 antagonists”) 
and their mechanism of action. The current status of the small molecule CCR5 inhibitor 
pipeline, with emphasis on the generation of resistance, including in vitro and in vivo HIV 
escape pathways and mechanisms, will be presented, while implications as well as future 
perspectives for the clinical use of CCR5 inhibitors will be discussed.  
2. The HIV entry process and the coreceptors 
2.1. Discovery of the HIV coreceptors 
CD4 had been known to be the principal cell surface receptor for HIV-1, and also for HIV-2 
and simian immunodeficiency virus (SIV), since 1984 [7, 8]. It had also been known for 
almost as long, however, that the presence of the CD4 antigen alone was not sufficient to 
allow for HIV entry. To infect CD4+ cells, HIV-1 strains of different biological phenotypes, 
namely macrophage (M)-tropic and T-cell line (T)-tropic, were supposed to utilize different 
auxiliary co-factors [9], the identity of which remained elusive until early 1996. At that time, 
a member of the seven-transmembrane (7-TM) spanning family of chemokine receptors 
initially termed “fusin”, was identified as the coreceptor for T-tropic HIV-1 variants [10]; the 
term was changed to C-X-C chemokine receptor type 4 (CXCR4) once its natural ligand was 
discovered to be stromal derived factor-1 (SDF-1)/CXCL12 [11, 12]. CXCR4 had been 
previously identified as an orphan receptor called leukocyte-derived seven-transmembrane 
domain receptor (LESTR), but it only received attention after its isolation as an HIV-1 
coreceptor [13].  
The knowledge that the β-chemokines macrophage inflammatory protein (MIP)-1α/CCL3, 
MIP-1β/CCL4 and regulated upon activation normal T-cell expressed and secreted 
(RANTES)/CCL5 exhibited antiviral activity against M-tropic HIV-1 isolates in vitro [14], 
provided the basis for the discovery of C-C chemokine receptor type 5 (CCR5) as the entry 
co-factor for these strains by five groups simultaneously [15-19]. The virus thus uses 
chemokine receptors, mainly CCR5 and CXCR4, to enter susceptible cells, while the cognate 
chemokine ligands act as natural entry inhibitors. Other chemokine receptors may also 
function as HIV coreceptors; nonetheless, infection of primary cells via alternative 
coreceptors is rare and the process can normally be fully blocked by CCR5 or CXCR4 
inhibitors [20-22]. Hence, at present, CCR5 and CXCR4 are considered as the only HIV 
coreceptors of physiological significance. 
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2.2. Physiological roles of the main coreceptors  
CCR5 and CXCR4 are two structurally related, heptahelical chemokine receptors that belong 
to different classes [C-C and CXC, respectively, based on the position of the two conserved 
cysteine (Cys) residues in their N-termini (Nt)] of the superfamily of G protein-coupled 
receptors (GPCRs) (reviewed in [13, 23-25]). About half of the drug targets in the 
pharmaceutical industry are GPCRs, which also, not coincidentally, comprise the largest 
family of cell-surface receptors [26]. GPCRs become activated by chemokines, small (8-10 
kDa) soluble protein ligands that are either promiscuous or specific for a given receptor. 
Once activated by such extracellular signals, GPCRs undergo conformational changes that 
trigger the intracellular signal transduction cascade; these series of events begin with the 
rapid phosphorylation by G protein-coupled receptor kinases (GRKs) predominantly on 
serine (Ser) and threonine (Thr) residues within the C-tail and third intracellular loop and 
continue with the activation of heterotrimeric G proteins [27]. In this mode, chemokines and 
their receptors control cell migration associated with routine immune surveillance, 
inflammation and development [28]. 
CCR5, in particular, appears to play a role in the initiation of adaptive immune responses 
and the trafficking of effector cells to sites of infection and inflammation as indicated by its 
expression profile on several effector T cell subsets and antigen-presenting cells, including 
macrophages, immature dendritic cells and Langerhans cells (reviewed in [22, 29, 30]). 
Nonetheless, the lack of expression of this gene due to a deletion polymorphism known as 
“delta32” does not appear to have any deleterious effects; in fact, heterozygosity for the 
CCR5∆32 allele is generally associated with delayed disease progression, and homozygosity 
with incomplete protection from HIV transmission (reviewed in [31]). The observation that 
its congenital absence does not lead to any overt pathology suggested that CCR5 might be a 
valid target for pharmacological blockade.  
CXCR4, on the other hand, and its single known ligand SDF-1/CXCL12 are both highly 
conserved [13]; they play an essential role during embryonic development and in several 
major processes in the adult, including hematopoiesis, leukocyte trafficking in the adaptive 
immune system, and vascularization [22]. CXCR4 knockout mice show hematopoietic and 
cardiovascular defects during embryogenesis and die in utero; mice lacking SDF-1/CXCL12 
are characterized by deficient B-lymphopoiesis and myelopoiesis and abnormal neuronal 
and cardiovascular development [13]. Clinically tested CXCR4 inhibitors AMD3100, which 
lacked oral bioavailability, and AMD070 caused significant leukocytosis (reviewed in [22]). 
The non-cyclam antagonist AMD070 (or AMD11070) is currently in Phase II clinical trials as 
an HIV cell-entry inhibitor [32]. The development of AMD3100 (by AnorMED) for use in the 
treatment of HIV infection was terminated, but further studies led to a new indication for 
this drug; AMD3100 (now Plerixafor, Genzyme) has been approved by the US Food and 
Drug Administration (FDA) for autologous transplantation in patients with non-Hodgkin’s 
lymphoma and multiple myeloma [32]. The fact that Plerixafor is well tolerated in the 
developed organism minimizes the concerns of antagonizing such a crucial receptor/ligand 
axis in mature individuals. CXCR4 antagonists could be used in combination with 
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antiretrovirals targeting other steps of the viral life cycle; they could also be administered 
simultaneously with CCR5 antagonists, even as one compound with high affinity for both 
receptors, as suggested recently [32]. Down-modulating the expression of CXCR4 may 
certainly be beneficial for some HIV patients [13]. The pharmacologic targeting of CXCR4 
may additionally have therapeutic utility for the treatment of acute viral infections of the 
central nervous system (CNS) [33]. The rest of this chapter focuses on issues related to the 
development of CCR5 inhibitors. 
2.3. The coreceptors in HIV entry 
Conformationally masked by carbohydrate structures and variable amino acid loops that 
enable it to evade the humoral immune response, the envelope glycoprotein (Env) on 
virions is organized into trimers of noncovalently associated surface gp120 and 
transmembrane gp41 heterodimers (reviewed in [34]). The interaction of HIV with host cell 
surface receptors trigger the fusogenic potential of Env and allow the virus to enter into its 
target cells by fusion, presumably at the plasma membrane [35]. The process has long been 
assumed to occur at the cell surface for such pH-independent viruses as HIV [36], although 
recent studies support the notion that HIV enters disparate cell types through fusion with 
endosomes [37, 38]. A schematic of the first steps of the HIV entry process, according to the 
presently accepted molecular mechanism, is shown in Figure 1.  
 
Figure 1. Schematic diagram of the first steps of the HIV entry process. (A) HIV entry into target cells 
is mediated through the interaction of the viral envelope glycoprotein (Env) with host cell surface 
receptors. (B) Surface gp120 first contacts CD4 and then (C) a chemokine receptor, typically CCR5 or 
CXCR4, triggering molecular rearrangements in the gp41 that result in membrane fusion and the 
initiation of infection. 
HIV entry begins with the high affinity binding of gp120 to the host cell CD4, which induces 
a major conformational change in Env that exposes or creates a binding site on gp120 for the 
coreceptor, typically either CCR5 or CXCR4. Current structural models suggest that the 
gp120 “bridging sheet”, formed between the constant C1, C2, and C4 domains of gp120 after 
CD4 binding, interacts with the tyrosine (Tyr)-sulfated coreceptor N-terminus (Nt), while 
the V3 crown interacts principally with the second extracellular loop (ECL2) region of the 
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coreceptor [39-42]. Coreceptor engagement of CD4-bound gp120 induces additional 
reconfigurations, leading to the insertion of the gp41 fusion peptide (FP) into the host cell 
membrane and the formation of a pre-fusion complex. This pre-fusion intermediate is then 
refolded into an energetically favorable six-helix bundle that brings the two membranes in 
close proximity so that fusion can occur; the viral core is thereby released into the cytoplasm 
and a new cycle of infection is initiated.  
Our understanding of HIV entry has provided invaluable insights into viral tropism and 
pathogenesis and led to the development of novel classes of antiretroviral agents that inhibit 
specific stages of the process. CCR5 inhibitors interrupt the viral replication cycle by 
preventing CCR5 binding and aborting fusion. 
3. Coreceptor use and HIV tropism  
3.1. Classification systems of HIV biological phenotype 
Before the identification of the coreceptors, three biological properties were the criteria used 
to classify the phenotype of HIV variants: (i) the preference for specific target cells (cellular 
tropism) that distinguished between macrophage (M)-tropic and laboratory T-cell line (T)-
tropic viruses; (ii) cytopathology, which distinguished between syncytium-inducing (SI) and 
non-syncytium-inducing (NSI) strains based on the capacity or not to form syncytia (i.e., 
giant multinucleated cells) through cell fusion in the MT-2 cell line; and (iii) replicative 
capacity, which mainly considered the in vitro growth kinetics of viral strains in culture and 
distinguished between slow/low (S/L) and rapid/high viruses (R/H) (reviewed in [43]).  
The above dichotomies may be explained by the more precise, newly adopted classification 
system that is based on coreceptor usage; accordingly, viruses that use CCR5 alone or 
CXCR4 alone for cell entry are currently termed R5 and X4, correspondingly, while variants 
that can use either coreceptor with comparable efficiency are termed R5X4 [44]. A more 
appropriate designation for the latter is R5+X4 or D/M (Dual/Mixed), particularly when 
tropism has not been determined at the clonal level, since many R5X4 isolates are in fact 
mixtures of R5 plus X4 or, less commonly, either R5 plus dual (R5X4), or even R5 plus dual 
(R5X4) plus X4, clones [22]. The term R5X4 should thus be reserved for clones that are 
genuinely capable of using both coreceptors. 
3.2. Determinants of HIV biological phenotype and coreceptor tropism 
assessment 
The determinants of coreceptor choice, and thus of biological phenotype, have been mapped 
to the surface gp120 subunit of Env and primarily to the V3 domain. Swapping the V3 
region alone often suffices to switch the coreceptor tropism of a viral clone from R5 to X4 
and vice versa [45]. Furthermore, the charge of the V3 region appears to be an important 
parameter affecting biological phenotype and, tropism, although it alone cannot be used as a 
marker for phenotype prediction; in general, however, higher net charges (≥ +5) characterize 
X4 variants compared to the lower V3 region net charges (≤ +4) of R5 variants typically 
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associated with acute infection (reviewed in [43]). The increase of the overall positive charge of 
the V3 region that may switch the viral phenotype results from the introduction of basic amino 
acid residues at one of the two positions 11 and/or 25 of the V3 [46, 47], a property that may 
not be shared by the uncommon subtype C CXCR4-using strains (reviewed in [48]).  
Simple genotypic approaches undertaken for predicting coreceptor usage include the 
detection of positively charged amino acids at positions 11 and 25 (often referred to as the 
“11/25 rule”) and the determination of the total charge of V3, with the cut-off set at +5; 
heteroduplex tracking assays and various bioinformatics approaches are additional 
genotypic methods for determining HIV tropism (reviewed in [49-51]). Predictive 
algorithms of coreceptor usage have been developed based on genetic sequences in the V3 
region, but also taking into account genotypic correlates outside the V3, structural 
information and clinical data [48]. Apart from these genotypic tools, different phenotypic 
assays have been developed to assess HIV tropism. These phenotypic methods, which are 
reviewed elsewhere [49-52], include the original MT-2 assay or coreceptor usage assays 
using reporter cell lines, and cell-based assays that use different methodologies to generate 
env-recombinant or pseudotyped viruses with distinct detection systems. The Trofile assay 
(Monogram Biosciences, Inc., South San Francisco, CA; now Laboratory Corporation of 
America [LabCorp]) is the most widely used phenotypic test in clinical practice. In the new 
era of CCR5 inhibitors, an accurate determination, and perhaps quantification, of coreceptor 
usage is necessary for the successful clinical management of HIV-infected individuals.  
3.3. HIV phenotypes, tropism and disease course 
Regardless of the route of HIV transmission, R5 viruses seem to prevail in the vast majority 
of primary and early stage HIV infection cases, whilst the X4 phenotype evolves in vivo in 
approximately 40-50% of (subtype B or D) infected subjects, usually 5–7 years after infection 
(reviewed in [43, 53]). Recent transmitted/founder virus genetic studies confirmed that only 
R5 (and typically a single R5 virus isolate) and in a few instances R5X4, but not X4 HIV-1, 
are initially transmitted [54, 55]. Consequently, a “gatekeeper” that nearly always selects 
transmission of R5 over X4 HIV may well exist. The suppression of X4 transmission has 
been suggested to result not from one powerful gatekeeper, but from an aggregate of 
multiple functional gatekeepers, the localization and precise molecular mechanisms of 
which remain to be determined (reviewed in [56]). CCR5 thus has a pivotal role in viral 
transmission, but infection by X4 (or R5X4) viruses is not impossible as indicated by the few 
known cases of HIV acquisition by CCR5-∆32 homozygotes; the lower pre-AIDS viral loads 
and slower disease progression of CCR5-∆32 heterozygotes, in whom the CCR5 expression 
levels on target cells are lower, underscore the importance of the CCR5 coreceptor in the 
early asymptomatic stages of the infection [31, 53].  
The emergence of X4 viruses in a proportion of cases correlates with accelerated disease 
progression [43, 53]. The virological or immunological basis of the selection mechanism is 
still debated; in other words, it is still unclear whether disease progression is accelerated as a 
direct consequence of the emergence or predominance of X4 isolates, or, conversely, 
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whether the declining competence of the host immune system permits the outgrowth of 
viral strains with increased replicative capacity [43]. The pathogenicity of X4 viruses seems 
to be greater than that displayed by R5 strains both in vitro and probably in vivo, as 
suggested by experiments in macaques [22]. R5 viruses alone can also cause severe damage 
to the immune system; X4 viruses are never detected in about half of HIV-infected subjects 
who do progress to AIDS [22, 53]. These late-emerging, R5 viral strains, which have reduced 
sensitivity to entry inhibitors and increased ability to cause CD4+ T-lymphocyte loss, also 
possess an improved ability to utilize relatively low levels of CD4 and CCR5 expressed on 
macrophages (reviewed in [57]). Correlations between increased gp120 net charge, enhanced 
viral fitness, and augmented cell attachment were disclosed as well for these R5 HIV-1 
variants that emerge in an opportunistic manner during severe immunodeficiency [58]. 
Different CD4+ T cell subpopulations are targeted by the phenotypic variants of HIV: 
replication of R5 viruses is favored in activated, memory/effector T cells, whereas X4 viruses 
may additionally infect intrathymic T progenitor cells and naïve T cells in the peripheral 
lymphoid system [39, 43]. Of note is the massive depletion in the gut-associated lymphoid 
tissue (GALT) of CCR5-expressing memory CD4+ T cells as a consequence of acute HIV 
infection (reviewed in [59]). The engagement by gp120 of integrin α4β7, the gut homing 
receptor, facilitates infection of CD4+ T cells in the earliest stages of transmission [60]. HIV 
replicates intensively first in the GALT and then systemically in all lymphoid tissues, where 
it establishes stable viral reservoirs (in the form of latently infected resting CD4+ T cells at 
the cellular level) that constitute major impediments to virus eradication [59]. The switch in 
coreceptor usage at the peak of viral diversity expands virus accessibility to circulating 
naïve CD4+ T cells, thereby increasing viral burden and leading to rapid CD4+ T cell 
depletion [61, 62]. The regenerative capacity of the immune system is also affected by the X4 
emergence or predominance since chronic immune activation is then exacerbated. T cell 
homeostasis is disrupted, eventually leading to the collapse of the immune system [43].  
4. The development of CCR5 inhibitors as anti-HIV therapeutics – Focus 
on small molecules 
As discussed above, the first clues regarding the potential therapeutic utility of targeting 
CCR5 came from the observation of the naturally occurring blockade of the coreceptor due 
to the CCR5∆32 polymorphism. Recently, the first successful allogeneic stem cell 
transplantation has been reported in an HIV-positive, acute myeloid leukemia patient from 
Berlin with a CCR5∆32 homozygous donor [63]. Investigators claimed to have “cured” this 
HIV-infected patient as indicated by the functional reconstitution of his T cell immunity 
without any signs of viral rebound after the discontinuation of ART [64]. The long-term 
effects of stem cell transplantation remain nevertheless unknown. Even though it would 
obviously be impractical to follow such a therapeutic approach in the millions of HIV-
infected subjects worldwide, the proof-of-principle case of “the Berlin patient” demonstrates 
that a functional cure, i.e. a permanent suppression of viral replication in the absence of 
ART, may be within reach, under certain circumstances, at present; a true sterilizing cure 
with complete eradication of the virus continues to be the ultimate goal of therapy [6]. 
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Towards this goal, there has been hope that CCR5 inhibitors will make an impact on 
controlling the epidemic by enhancing our therapeutic arsenal against HIV.  
It should be noted, however, that the development of these host-targeting agents raises 
additional safety concerns that lie beyond the typical pharmacological concerns associated 
with the development of any antiretroviral drug, such as efficacy, safety and tolerability, 
bioavailability, drug-drug interactions, and the emergence of escape mutants (reviewed in 
[22, 65]). These safety concerns stem from the disruption of the physiological functions of 
the coreceptor as well as from the potential escape of R5 viruses by switching coreceptor use 
to CXCR4, or the breakthrough of X4 viruses following the suppression of R5 strains [22, 65]. 
The latter virological concern will be discussed in the next section on the generation of 
resistance to CCR5 inhibitors. The absence of any apparent immunological deficits of 
significance among individuals with naturally occurring loss-of-function mutations (i.e., 
CCR5∆32 homozygotes) provides some reassurance that pharmacological blockade of CCR5 
will be relatively benign [66]. Redundancy in the chemokine network presumably allows 
other chemokine receptors to subsume the function of CCR5 [67]. However, the abrupt 
pharmacological blockade of a receptor in mature individuals may have different 
consequences than the congenital absence of the receptor where the immune system has had 
years to adapt to its loss [22, 67]. Corroborating the results of previous studies in mice 
(reviewed in [67]), studies in humans have shown that CCR5∆32 heterozygotes have a six-
fold increased risk for severe West Nile virus (WNV) infection and a five-fold increased risk 
of mortality [68]. A meta-analysis of the four patient cohorts in the United States confirmed 
that CCR5 deficiency is a strong and consistent risk factor for symptomatic WNV infection 
[69]. An additional association between the lack of functional CCR5 due to the CCR5∆32 
deletion and tick-borne encephalitis has also been reported [70]. Overall, however, currently 
available data suggest that pharmacological blockade of CCR5 is likely to be largely well 
tolerated; stringent safety studies will nevertheless be required to monitor the long-term 
safety of CCR5 blockade, with particular attention paid to the consequences of infection by 
certain pathogens, effects on responses to immunization, and the emergence of 
opportunistic infections and malignancies [22, 65].  
Several different approaches have been undertaken to pharmaceutically target CCR5, 
including the use of chemokine analogues, anti-CCR5 antibodies, gene knockdown and 
knockout strategies, and small molecule coreceptor inhibitors. The development of 
coreceptor inhibitors for use in prevention, including topical microbicides, is discussed 
elsewhere [22, 67]. 
4.1. Chemokine analogues 
Chemokine analogues engineered to enhance their natural anti-HIV properties were the first 
generation of CCR5 inhibitors (reviewed in [22, 71, 72]). RANTES, an N-terminally 
truncated variant of RANTES/CCL5 was the first such engineered analogue, but it was 
found to exhibit only modest anti-HIV activity. Its identification nonetheless helped 
establish the concept that the agonist activity on coreceptors is not a component of the anti-
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HIV mechanism of native chemokines. Further N-terminal modifications led to the 
generation of chemokine analogues such as AOP-RANTES [73] and PSC-RANTES [74], 
which have improved potency due to their mechanism of action; they induce receptor 
sequestration that results in the internalization and physical removal of the coreceptor from 
the cell surface, effects that are more profound and prolonged compared to those of native 
chemokines [22]. The clinical development of chemokine analogues as anti-HIV therapeutics 
is complicated by the fact that as proteins, chemokines would not be expected to be orally 
bioavailable and their production costs would be prohibitively high; moreover, chemokine 
analogues are unlikely to show suitable pharmacokinetics after injection because they 
readily bind to and form aggregates on cell surface proteoglycans [22]. The potential adverse 
effects due to the possible inflammatory activity mediated through CCR5 activation is 
another concern associated with their use. 
4.2. Anti-CCR5 antibodies 
Most anti-CCR5 monoclonal antibodies (MAbs) have been described as chemokine 
antagonists that inhibit the receptor via steric blockade (reviewed in [22]). Many rodent anti-
CCR5 MAbs with anti-HIV activity have been identified and extensively characterized. PRO 
140 (Progenics pharmaceuticals) is a humanized monoclonal antibody, currently available 
only for parenteral administration; PRO 140 received fast-track approval by the FDA. The 
efficacy, tolerability and toxicity profiles of PRO 140 have been assessed by several 
preclinical and clinical studies, which showed promising results (reviewed in [75]). Of note 
is the evidence of activity shown by PRO 140 against escape mutants with cross-class 
resistance to small molecule CCR5 inhibitors [76]; however, as a complex biological 
molecule requiring parenteral administration, PRO 140 faces a different set of development 
challenges compared to the orally bioavailable small molecule compounds [77]. Human 
CCR5mAb004 antibody also performed well in early clinical trials [22]. Currently available 
data further suggest that anti-CCR5 MAbs act synergistically with other CCR5 inhibitors 
and have different resistance profiles. Their typically long circulatory half-lives do not 
necessitate frequent dosing, suggesting that the lack of oral bioavailability may not be a 
serious limitation in their development as anti-HIV drugs. 
4.3. Gene knockdown and knockout strategies 
CCR5 expression in HIV-1 target cells can be suppressed by RNA-based gene modulation 
technologies such as RNA interference (RNAi), or completely eliminated by such 
techniques as zinc finger nuclease (ZFN)-mediated gene disruption. RNAi refers to the 
sequence-specific degradation of messenger RNA (mRNA) that follows the cellular 
introduction of homologous, short-interfering RNA (siRNA), a technique that has 
emerged as a powerful tool to probe the function of genes of known sequence in vitro and 
in vivo [78, 79]. RNAi has been shown to decrease the replication of HIV-1 in lymphocytic 
cells using siRNA targeting both viral (e.g., Tat, Gag and Rev) and host proteins, 
including CD4 and CCR5 (reviewed in [80]). The numerous challenges associated with 
converting RNAi from a laboratory technique to an anti-HIV therapeutic have been 
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reviewed elsewhere [22]. Recent advances in the development of RNAi-based therapeutics 
for HIV-1 are presented by Zhou and Rossi [81]. Zinc-finger nucleases (ZFNs) are artificial 
restriction enzymes engineered by fusing a zinc finger DNA-binding domain to a DNA-
cleavage domain; the generated double-stranded DNA break is repaired by the 
endogenous DNA repair machinery of the cell, potentially leading to the permanent 
disruption of the gene’s open reading frame [82]. CCR5 gene knockout in T cells or 
hematopoietic stem/progenitor cells (HSC) by ZFNs effectively suppresses the replication 
of CCR5-tropic strains of HIV-1 in animal models (reviewed in [83]). ZFNs are currently 
being evaluated in a phase I clinical trials using ex vivo expanded T cells; HSC targeted 
therapies are under development as well. 
4.4. Small molecule CCR5 inhibitors  
Small molecule CCR5 inhibitors (Table 1) prevent HIV-1 from entering its target cells, 
mainly CD4+ T cells and macrophages, by blocking the CD4-dependent binding of the viral 
surface envelope glycoprotein (gp120) to the most commonly used coreceptor CCR5 
(reviewed in [22, 67, 72, 77]).  
The identification of the first such molecule, TAK-779, in 1999 [84] was followed by several 
reports on additional CCR5 inhibitors with improved potency and more favorable 
pharmacological properties (Table 1). The development of these compounds has been 
principally pursued for the treatment of HIV-1 infection, although, theoretically, they could 
also be used as preventive agents [98]. Maraviroc (MVC, Selzentry; Pfizer, Inc., Figure 2A) 
was the first, and so far only, small molecule CCR5 inhibitor to be approved for treating 
HIV-1 infection by the US FDA and by the European Agency for the Evaluation of Medicinal 
Products (reviewed in [99]). MVC is licensed for administration in both treatment-naïve (i.e., 
yet to receive any ART) and in treatment-experienced patients with R5 HIV-1. Other 
investigational compounds have also entered clinical trials, but a number of them were 
discontinued due to observed side effects (Table 1). The development of Vicriviroc (VCV, 
Schering-Plough Research Institute; now Merck Research Laboratories, Figure 2B) was 
abandoned because it did not meet primary efficacy endpoints in late stage (Phase III in 
treatment-experienced subjects and Phase II in treatment-naïve individuals) clinical trials. 
Additional compounds are in preclinical or clinical development (reviewed in [77]). 
Previously designated as TBR-652 or TAK-652 (Figure 2C), cenicriviroc is a small-molecule 
CCR5 antagonist licensed by the Takeda Pharmaceutical Company to Tobira 
Pharmaceuticals; cenicriviroc has pharmacokinetic data supportive of once daily dosing and 
a favorable tolerability profile in single-dose studies in healthy volunteers. PF-232798 
(Figure 2D), a second-generation small-molecule oral CCR5 antagonist with potency similar 
to MVC and the potential for once daily dosing, has demonstrated activity against a 
laboratory-generated MVC-resistant R5 virus. INCB9471 (Incyte, Wilmington, DE, USA) is 
yet another small-molecule oral CCR5 inhibitor that showed promising results in a Phase IIa 
trial in treatment-naïve and treatment-experienced patients with once daily dosing over 14 
days [77]. 
 
Chemokine Receptors as Therapeutic Targets in HIV Infection 
 
125 
Drug Other names Key features Manufacturer Current 
status 
References 
TAK-779 N/A (Nonpeptidic) quaternary 
ammonium anilide that 
prevents gp120 and CC-
chemokines, but not anti-CCR5 
MAbs, from binding to CCR5 
Takeda  Preclinical 
only 
[84] 
Cenicriviroc TBR-652,  
TAK-652 
Orally bioavailable, improved 
potency TAK-779-derivative; 
also blocks CCR2  
Takeda;  
now Tobira 
Phase II 
completed 
[85, 86] 
AD101 SCH-350581 Piperidino-piperazine-based 
compound structurally related 
to, but more potent than SCH-
C; also blocks MAbs mainly 
against the ECL2 of CCR5 
Schering-
Plough  
Preclinical 
only  
[87, 88] 
SCH-C  SCH-351125 Oximino-piperidino-piperidine 
amide that also blocks MAbs 
mainly against the ECL2 of 
CCR5; unable to exert its 
antiviral effects when residue 
198 in TM helix 5 of CCR5 is 
methionine (Met) as in rhesus 
macaques [89] 
Schering-
Plough  
Discont-
inued; 
hERG K+ 
channel 
blockade 
& CNS 
side effects 
[90-92] 
Vicriviroc  
(VCV) 
SCH-D,  
SCH-417690, 
VVC 
Piperazino-piperidine-based 
compound; improved potency 
& pharmacokinetics, reduced 
tendency for hERG channel 
blockade compared to SCH-C 
Schering-
Plough;  
now Merck  
Discont-
inued 
from 
Phase III; 
primary 
efficacy 
points 
unmet 
[93, 94] 
Aplaviroc  
(AVC) 
AK602/ONO41
28/873140, 
GW873140, 
APL 
Spirodiketopiperazine-based 
compound; it preserves 
RANTES and MIP-1β binding 
to CCR5+ cells and their 
functions 
Glaxo 
SmithKline 
Discont-
inued 
from 
Phase 
IIb/III; 
idiosyncra
tic 
hepatotoxi
city 
[95] 
Maraviroc  
(MVC, 
Selzentry) 
UK-427,857 Spirodiketopiperazine with 
favorable pharmacological 
properties 
Pfizer Approved 
for clinical 
use 
[96, 97] 
hERG K+, human ether-a-go-go related gene potassium channel; MAb, monoclonal antibody; N/A, not applicable. 
 
Table 1. Nomenclature, characteristics, and developmental status of selected small molecule CCR5 
inhibitors  
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Figure 2. Chemical structures of selected small molecule CCR5 inhibitors. A. Maraviroc (MVC, 
Selzentry), B. Vicriviroc (VCV), C. Cenicriviroc (TBR-652), D. PF-232798. 
Binding site. The binding site of small molecule CCR5 inhibitors does not overlap with the 
binding site for HIV gp120. In the absence of a high-resolution structure of a gp120-
coreceptor complex, biochemical studies of CCR5 have revealed the importance of its N-
terminus (Nt) and second extracellular loop (ECL2) in binding gp120 and mediating viral 
entry (reviewed in [34]). Small molecule CCR5 inhibitors, on the other hand, are believed to 
bind within a cavity between the transmembrane (TM) helices on the extracellular surface of 
the coreceptor, as suggested by site-directed mutagenesis experiments and molecular 
modeling of CCR5 on the basis of the available crystal structure of bovine rhodopsin that is 
characterized by a similar TM topology [100, 101]. More specifically, the binding “pocket” of 
such molecules as TAK-779, AD101, and SCH-C is thought to be located between TM helices 
1-3, and 7; other TM helices, particularly helix 6, contribute to some compound-specific 
variations [102, 103]. Simultaneous administration of multiple antagonists showed that, 
indeed, they bind to a common site on CCR5 [104]. A key set of aromatic and aliphatic 
residues that serve as a hydrophobic core for this ligand binding pocket has also been 
identified, while a glutamic acid (Glu) in helix 7, E283, appears to be critical for high affinity 
interaction; this residue probably acts as the counterion for a positively charged nitrogen 
atom common to TAK-779, AD101, and SCH-C [105]. 
The binding of all small molecule CCR5 antagonists to a broadly similar site within the TM 
helices of the coreceptor renders cross-resistance within this drug class possible, but not 
necessarily inevitable since compound-specific variations with respect to properties such as 
structure, shape, and electrostatic potential, do exist [106]; hence, despite the insensitivity of 
AD101 escape mutants to all other tested CCR5 inhibitors, including SCH-C, aplaviroc 
(AVC), MVC and VCV [107-109], a MVC-resistant variant has been reported to retain its 
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sensitivity to SCH-C and AVC [110]. Susceptibility to other classes of licensed drugs that 
target different stages of the viral life cycle, or even different steps of the same stage of the 
viral life cycle such as viral entry, should be maintained. Accordingly, clinical resistance to 
Enfuvirtide (ENF, Fuzeon/T-20) was not found to affect viral sensitivity to the fusion 
inhibitor T-1249 or to coreceptor inhibitors [111]. 
Mechanism of action. Small molecule (molecular weight 500-600 D) CCR5 inhibitors act via 
a similar, allosteric (from the Greek “allos”+“stereos” meaning “other”+“shape,” respectively) 
mechanism; in other words, they induce or stabilize a conformation of the coreceptor that 
renders it unrecognizable by the wild-type virus. The results of recent biochemical studies 
support the noncompetitive and allosteric nature of the mechanism of action of small 
molecule antagonists of CCR5 [104]. The difference in binding sites between the two ligands 
also supports the allosteric modulation of the HIV-1 gp120 binding site by this class of 
drugs; as mentioned above, CCR5 inhibitors bind within the TM helices in the extracellular 
facet of the coreceptor, whereas HIV gp120 targets the extracellular domains of CCR5 and, 
more specifically, the negatively-charged Tyr-sulfated amino terminus (Nt) and the ECL2 
between TM helices 4 and 5 [103].  
Moreover, the action of some CCR5 inhibitors may be blocked by the introduction of certain 
mutations into CCR5 despite the binding of the inhibitor to the coreceptor; namely, the 
antiviral effects of SCH-C are blocked, although its antagonism of the signaling by 
RANTES/CCL5 persists, when residue 198 in the TM helix 5 of CCR5 is methionine (Met) as 
in rhesus macaques [89]. This observation led to the hypothesis that the I198M substitution 
may be involved in the induction of a CCR5 conformation that is incompatible with HIV-1 
infection. It should be noted, however, that not all CCR5 inhibitors are modulated in the 
same manner by this amino acid change. I198M has been shown not to block the antiviral 
effects of AD101, whereas another mutation, F113A, may block the inhibitory action of 
AD101, but not of SCH-C, via a similar mechanism [89]. Further subtle differences exist in 
the stabilized or induced conformations by the binding of these small molecules to the TM 
pocket of CCR5 and, therefore, in the mechanism of action of these compounds. For 
instance, although most CCR5 inhibitors antagonize potently the three natural ligands of the 
coreceptor, AVC only antagonizes MIP-1α/CCL3 efficiently and much less potently the 
other two ligands (MIP-1β/CCL4, and RANTES/CCL5) [95].  
Displacement binding assays and dissociation kinetics demonstrated that TAK779 and MVC 
inhibit CCL3 and gp120 binding to CCR5 by a noncompetitive and allosteric mechanism, 
supporting the view that these compounds bind to regions of CCR5 distinct from the gp120- 
and CCL3-binding sites [112]. MVC is predicted to insert deeply in the CCR5 TM cavity 
where it can occupy three different binding sites, whereas CCL3 and gp120 lie on distinct, 
yet overlapped regions of the CCR5 ECL2 [113]. TAK779 and MVC were found to be full 
and weak inverse agonists for CCR5, respectively, indicating that they stabilize distinct 
CCR5 conformations with impaired abilities to activate G-proteins [112]. The finding that 
the TM cavity remains accessible for MVC in CCL3-bound and gp120-bound CCR5 [113], 
provides an explanation for the enhancement by TAK779 and MVC of the dissociation of 
 
Immunodeficiency 
 
128 
preformed ligand-CCR5 complexes with an efficiency that correlates with their ability to act 
as inverse agonists [112]. The identification of residues mandatory for gp120 binding in the 
predicted CCR5 dimer interface suggests that receptor dimerization might represent a target 
for new CCR5 entry inhibitors [113]. 
AK530 and AK317, two CCR5 inhibitors containing spirodiketopiperazine scaffolds, lodge 
in a hydrophobic cavity located between the upper TM domain and the ECL2 of CCR5 [114]. 
The interaction profile of the inhibitors with ECL2 residues S180 and K191 was found to be 
an important determinant of antiviral potency; furthermore, amino acid residues in the beta-
hairpin structural motif of ECL2 were critical for HIV-1-elicited fusion and binding of these 
spirodiketopiperazine-based inhibitors to CCR5. The direct ECL2-engaging property of the 
inhibitors likely produces an ECL2 conformation, which HIV-1 gp120 cannot bind to, but it 
also prohibits the virus from utilizing the “inhibitor-bound” CCR5 for cellular entry - a 
mechanism of HIV-1's resistance to CCR5 inhibitors, as discussed in the next section. 
5. Generation of resistance to small molecule CCR5 inhibitors 
The most parsimonious escape pathway from the selection pressure of a CCR5 inhibitor 
would be coreceptor switching to CXCR4 use, with its well documented devastating 
consequences on the rate of CD4+ T cell depletion and disease progression of patients [22, 53, 
67]. Both in vitro and in vivo studies have nevertheless shown that this is not the preferred 
escape pathway by HIV-1 despite the short distance in sequence space (few mutations) that 
separate R5 from X4 variants. The reduced replication fitness or the suboptimal coreceptor 
use, as indicated by the increased sensitivity to the selecting CCR5 antagonist of viral 
intermediates in the R5 to X4 evolution process compared to baseline virus, may account for 
this apparently paradoxical phenomenon; the requirements of inserting charged amino 
acids at specific locations and the strong bias in favor of G-to-A substitutions rather than 
random mutations are thought to impose additional constraints on the transition [115, 116]. 
Whatever the reasons may be, when R5 viruses escape from the selection pressure of CCR5 
inhibitors they tend to retain the R5 phenotype.  
Several factors diversify the pathways of resistance development to CCR5 inhibitors 
compared to those to conventional antiretroviral drugs [22]. The seemingly facile, for HIV, 
escape pathway of mutating the active site of a viral enzyme in order to prevent the binding 
of an antiviral would simply not work in the case of CCR5 antagonists that target a host- 
rather than a virus-encoded gene. Instead, the virus must devise a strategy to recognize and 
use the coreceptor to gain access into its target cells despite the presence of the inhibitor. The 
highly variable nature of the env gene certainly facilitates the escape process; however, env is 
also under the constant selection pressure from neutralizing antibodies [34]. Thus, during 
the development of resistance to CCR5 inhibitors the HIV-1 Env complex must 
accommodate sequence changes that enable the virus to escape both from the selection 
pressure of the inhibitors as well as from the humoral immune response, without violating 
the structural constraints of the Env protein.  
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5.1. In vitro resistance: No coreceptor switch to CXCR4 and no uniform 
genotypic signature 
To gain insights into what may happen in vivo if or when small molecule CCR5 inhibitors 
are used more extensively, resistance is first studied in vitro. To generate resistant variants, 
primary R5 isolates are cultured with physiological target cells that are permissive for 
replication of both R5 and X4 viruses in the presence of increasing concentrations of the 
inhibitor under study. Despite the intrinsic difficulty associated with the selection process in 
each case that proved to require prolonged periods of culture in the presence of these 
compounds, several such studies have been published (reviewed in [22, 72, 117]). An 
alternative in vitro system that allows for the selection of escape mutants to CCR5 inhibitors 
over a relatively short period of time is the construction of V3 loop libraries of R5 infectious 
clones (reviewed in [118]). The results of these studies collectively show that the escape 
mutants tend to retain usage of CCR5 despite the availability of CXCR4. The mechanism 
that allows resistant viruses to continue to use CCR5 in the presence of the inhibitor is 
discussed in the next section. X4 viruses have been observed in CCR5 inhibitor-selection 
experiments, either in the control culture alone [119] or in both the selection and the control 
cultures [110], but their emergence was probably due to adaptation to growth in culture 
rather than the inhibitor escape process. Conditional recognition of CXCR4 in specific cell 
lines has also been reported for one VCV-resistant virus [109]. HIV-1 can be “forced” to 
escape CCR5 drug pressure through coreceptor switch under certain experimental 
conditions, which may not be very relevant physiologically [120].  
To date, no clear signature resistance mutations have been identified for CCR5 antagonists 
and different genetic pathways can lead to the same resistance phenotype (Table 2).  
The determinants of resistance commonly map to the V3 region of gp120, a localization that 
is consistent with the highly variable nature of this region as well as with its role in 
coreceptor engagement [22, 45]. Four V3 substitutions (K305R, H308P, A316V and G321E) 
were, for example, responsible for the resistant phenotype of isolate CC101.19 when the 
CCR5-using, subtype B virus CC1/85 [62] was cultured with the small molecule CCR5 
inhibitor AD101, a preclinical precursor of VCV [107, 108]. A much rarer route to resistance 
was undertaken by viruses derived from the same CC1/85 lineage in an AD101/VCV 
selection culture [109]; the resulting D101.12 escape mutants contained at least one 
substitution in V3 (H308P) as well as either of the following combinations of substitutions 
within and downstream of the gp41 fusion peptide (FP): G514V+V535M (Pattern I) or 
M518V+F519L+V535M (Pattern II) [127]. We have also described a unique VCV escape 
pathway for viruses from the D1/85.16 lineage that involved no V3 changes; instead, 
resistance mapped to three conservative substitutions in the FP: G516V, M518V and F519I 
[126]. As shown recently [131], the G516V change is critical to VCV resistance, although it 
must be accompanied by either M518V or F519I to have a substantial impact phenotypically. 
Nevertheless, introducing the three FP changes together into a heterologous virus, JR-FL, 
did not create a VCV-resistant variant [126]. CCR5 inhibitor resistance is usually dependent 
upon the Env genetic context and it is not transferred when introduced into other viruses 
[124, 126, 132], but that is not always the case [129].  
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  Resistance mutations  
 Parental virus gp120   
Drug Name Subtype V3 Elsewhere gp41 References 
TAK-779 JR-FLV3Lib B 
I304V, H305N, I306M, 
F312L, E317D 
None None [121] 
TAK-652 KK 
Unknow
n 
ND ND ND [119] 
AD101 CC1/85 B 
K305R, H308P, A316V, 
G321E 
None None [107, 108] 
VCV 
Clinical 
isolate 
C 
K305R, T307I, F316I, 
T318R, G319E and 
S306P 
None None [122] 
VCV 
Clinical 
isolate 
S91 
D Q315E, R321G 
E328K, 
G429R 
(C4) 
None [123] 
VCV RU570 G K305R, R315Q, K319T P437S (C4) None [124, 125] 
VCV CC1/85 B None None 
G516V, M518V,  
F519I  
[109, 126] 
VCV 
CC101.6 
(CC1/85 
passage 6 
AD101 
selection)  
B 
H308P and  
one or more of:  
K305R, A316V, G321E 
None 
G514V, V535M 
(Pattern I) or  
M518V, F519L, 
V535M (Pattern II) 
[109, 127] 
AVC 
Clinical 
isolates 
Unknown Several Several Several [128] 
MVC 
Clinical 
isolate 
B 
P/T308H, T320H, 
I322aV 
D407G, 
∆N386 
(V4)
None [129] 
MVC CC1/85 B A316T, I323V ND ND [110] 
MVC RU570 G ∆QAI (315-317) ND ND [110] 
MVC JR-FLV3Lib B 
I304V, F312W, T314A, 
E317D, I318V 
T199K, 
T275M 
(C2) 
None [130] 
ND, Not determined; I322aV occurs at an amino acid not present in HXB2 located between residues 322 and 323 and is 
designated 322a. 
Table 2. Genetics of HIV-1 escape from the selection pressure of small molecule CCR5 inhibitors  
The findings of these studies have important implications for the clinical use of small 
molecule inhibitors, particularly for the generation of genotypic algorithms and phenotypic 
assays to predict the emergence of resistant viruses and the likelihood of cross-resistance to 
other members of this drug class. Cross-resistance to other CCR5 antagonists may or may 
not arise with these molecules that retain sensitivity to all other drug classes (e.g. nucleoside 
and non-nucleoside reverse transcriptase inhibitors, protease and integrase inhibitors) as 
well as to other entry inhibitors acting at different stages of the entry process (e.g. the fusion 
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inhibitor enfuvirtide) [117]. Small molecule CCR5 inhibitors also retain sensitivity to anti-
CCR5 MAbs that act by a dissimilar mechanism.  
Viral fitness. When HIV-1 develops resistance to conventional antiretroviral drugs such as 
reverse transcriptase or protease inhibitors, its fitness is often impaired. To investigate 
whether the in vitro development of resistance to small molecule CCR5 inhibitors has an 
associated fitness cost, we developed a growth-competition assay involving dual infections 
with molecularly cloned viruses that are essentially isogenic outside the env genes under 
study. Real-time TaqMan quantitative PCR (QPCR) was used to quantify each competing 
virus individually via probes specific to different, phenotypically silent target sequences 
engineered within their vif genes. Head-to-head competition assays of env clones derived 
from the AD101 and VCV resistant isolate, the inhibitor-sensitive parental virus, and a 
passage control virus showed that CCR5 inhibitor resistance was not associated with a 
fitness loss [133]. This observation is consistent with the retention of the resistant phenotype 
when the escape mutant virus CC101.19 was cultured for a total of 20 passages in the 
absence of the selecting compound [133]. Amino acid substitutions in the V3 region of gp120 
that confer complete resistance cause a fitness loss when introduced into an inhibitor-
sensitive, parental clone; however, in the resistant isolate, changes elsewhere in env that 
occurred prior to the substitutions within V3, appear to compensate for the adverse effect of 
the V3 changes on replicative capacity. Hence, a decrease in fitness resulting from CCR5 
inhibitor resistance may not be as common as with the fitness loss observed with resistance 
to almost all other antiretroviral drugs (reviewed in [72]). 
The in vivo situation may differ, but further studies are needed to explore the fitness impact 
of HIV-1 with acquired resistance to CCR5 antagonists. In one case, pre-treatment V3 
sequences reemerged in a subtype C-infected patient following VCV discontinuation, 
implying that VCV resistance has associated fitness costs [122]. Nonetheless, all the VCV-
resistant isolates we have studied (CC101.19, D101.12 and D1/85.16) have highly stable 
phenotypes in peripheral blood mononuclear cells (PBMC), in that they do not rapidly 
revert to sensitivity when cultured without the inhibitor [108, 126, 127, 133]. During 
reversion experiments of individual resistant clones in the absence of the inhibitor, we 
discovered that M518V, which has little or no effect on VCV sensitivity on its own, appears 
to be under no pressure to revert either [131]. Val-518 is a naturally occurring FP 
polymorphism that becomes enriched during VCV or AD101 selection [126]. However, a 
resistant clone D1/85.16 cl.23 (= R) reverted to a sensitive phenotype by five weekly, VCV-
free passages in PBMC culture. Interestingly, the complete cluster of the three FP changes 
persisted within the genetic context of the gp120 derived from the resistant clone R; 
however, the three FP changes were accompanied by a Thr-to-Ala substitution at position 
244 of the second conserved region (C2) of gp120 that appears to counter the VCV-resistance 
phenotype created by the FP substitutions. This residue is located in strand β7, part of a β-
sandwich structure in the inner domain that is involved in CD4-induced conformational 
changes within gp120 and the interaction with gp41 [134-137]. Examining the interplay of 
these changes will enhance our understanding of Env complex interactions that influence 
both HIV-1 entry and resistance to CCR5 inhibitors. 
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Figure 3. Mapping residue 244 on the structure of the gp120 of the representative clone, CC1/85 cl.7, of 
the parental, inhibitor-sensitive virus CC1/85. Residue 244 (magenta) is located in strand β7, part of a β-
sandwich structure in the inner domain of gp120 that is thought to be involved in interactions with 
gp41. The CC1/85 cl.7 gp120 core structure was modeled based on the V3-containing structure of gp120 
[138] with Swiss-Model [139] using 2B4C.pdb as template and visualized using PyMOL [140]. 
5.2. Mechanisms of resistance to small molecule CCR5 inhibitors 
As portrayed graphically in Figure 4, resistance to small molecule CCR5 inhibitors may 
likely develop via two, not necessarily exclusive, mechanisms: competitive resistance and 
noncompetitive or allosteric resistance (reviewed in [22, 72, 117, 118, 141]), not to be 
confused with the competitive or not, properties of the inhibitors themselves [142]. Either 
mechanism may be effective at overcoming inhibition for some CCR5 inhibitors, while some 
HIV-1 escape mutants may undertake a combination of the two mechanisms. 
Understanding how resistance arises is relevant to how it is detected and quantified. 
Competitive resistance. Competitive resistance (Figure 4A) is defined as resistance that 
results in a shift in the IC50 of an inhibitor to a higher concentration; complete inhibition can 
still be achieved at sufficient inhibitor concentrations [142]. Competitive resistance could 
arise from more efficient utilization of inhibitor-free CCR5 to gain access into target cells; in 
turn, this could arise either from a greater affinity of Env for the coreceptor, or from an 
increase in the kinetics of Env-mediated fusion after CCR5 engagement. Either scenario 
would allow the virus to better compete with the inhibitor for the coreceptor, reflecting its 
adaptation to scavenge low levels of inhibitor-free CCR5 [142]. A partially (~5-fold) AD101-
resistant isolate had this ability [108]; however, this mechanism alone cannot count for 
complete resistance to CCR5 antagonists [117]. 
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A       B                C 
Figure 4. Resistance mechanisms for viral escape from CCR5 inhibitors. Model inhibition curves are 
displayed for sensitive and resistant viruses (solid grey and dashed black curves, respectively). The 
atypical dose-response curves of resistant viruses with gp41 fusion peptide (FP) mutations are shown in 
blue. A. Competitive resistance results in a shift in the IC50 of an inhibitor to a higher concentration, 
with complete inhibition potentially achievable at a high enough inhibitor concentration. B. In 
noncompetitive resistance, the IC50 values are typically equivalent to those for the sensitive virus, but 
the extent of inhibition is incomplete for the resistant virus. The maximum percent inhibition (MPI) 
value, at a saturating inhibitor concentration, reflects the efficiency with which the inhibitor-CCR5 
complex is used relative to free CCR5, thereby providing a measure of the degree of resistance of the 
HIV-1 variant under study. MPI values vary by cell type for inhibition by VCV and related compounds. 
C. In the novel paradigm of noncompetitive resistance, resistant FP mutant viruses display reduced 
MPI and IC50 values. Adapted from [143]. 
Noncompetitive or “allosteric” resistance. Noncompetitive resistance (Figure 4B) is defined 
as resistance that results in saturable inhibition, such that increasing concentrations of the 
inhibitor have no effect on the virus; the EC50 required to reach this saturation level is the 
same as the IC50 for the fully sensitive virus [142]. Phenotypically, resistance manifests as a 
plateau in the maximum achievable suppression of viral replication. The implication of this 
mechanism is that the resistant Env has adapted to use the inhibitor bound form of CCR5 as 
a coreceptor as well as, but not instead of, the free coreceptor [110, 142]. The level of residual 
inhibition, termed the “plateau” or the maximum percent inhibition (MPI), once inhibition 
has reached saturation reflects the efficiency with which the inhibitor-CCR5 complex is used 
relative to free CCR5; the higher the MPI value, the less efficiently a resistant virus uses the 
inhibitor-CCR5 complex [110, 142]. This mechanism is consistent with the allosteric mode of 
action of small molecule CCR5 inhibitors; these compounds lock the extracellular domains 
of CCR5 in a conformation that can be recognized only by resistant variants -in addition to 
the natural coreceptor-, but not by wild-type HIV-1 [117]. In a few instances, the preferred 
use of the inhibitor-bound CCR5 over the unbound receptor by some CCR5 antagonist-
resistant viruses leads to modestly increased replication of resistant viruses in the presence 
of the inhibitor in vitro [142]. The cell type influences the mode in which resistance to small 
molecule CCR5 inhibitors is manifested, particularly MPI values [110, 124, 126, 127, 131, 
142]. Moreover, the differences between the MPI values of VCV-resistant and sensitive 
viruses we have studied are generally much smaller in cell lines engineered to express 
CCR5, such as TZM-bl or U87.CD4.CCR5 (that serves as the basis of the PhenoSense and 
Trofile tropism assays), than in PBMC [126, 127, 131].  
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Resistant FP mutants: A novel paradigm of noncompetitive resistance. The VCV-resistant 
viruses carrying FP changes represent a novel paradigm of noncompetitive resistance 
(Figure 4C); apart from the plateau effect, these FP mutants paradoxically have lower IC50 
values than wild-type viruses, particularly in certain cell types (e.g. TZM-bl cells). Hence, 
although by one measure (MPI) the FP-mutant viruses display a modest level of resistance, 
by another (IC50) they appear to be hypersensitive [126, 127, 131]. To explain this paradox, 
we created a theoretical model of resistance [126]. The mathematical formulation of the 
model is presented in detail in the Supporting Information (SI) section of [126]. The model is 
based on the assumption that distinct forms of CCR5, with varying affinities (ranging from 
low to high) for small molecule CCR5 inhibitors, are present in different proportions on 
disparate cell types; these coreceptor forms, which could be conformers (conformational 
isomers) or differentially Tyr-sulfated forms, are used selectively by resistant HIV-1 variants 
when ligated with an inhibitor. According to the model, wild-type virus can use both forms 
of unligated CCR5 for entry, possibly with a preference between them, but it cannot enter 
via the inhibitor-coreceptor complexes. The resistant virus, on the other hand, uses 
preferentially the unoccupied high-affinity coreceptor and the occupied low-affinity 
coreceptor. Applying this model led to the generation of theoretical inhibition curves that 
closely mimic the experimental data for resistant viruses in each case [126, 127, 131]. Using 
the model, we have recently identified the third FP mutation, F519I, (of the V3-independent 
or FP only- genetic pathway to resistance) as an independent determinant of preference for 
the unoccupied, high-VCV affinity form of CCR5 [131]. Modeling the inhibition data from 
two cell types, PBMC and TZM-bl cells, suggested that D101.12, which harbors both V3 and 
gp41 substitutions, discriminates between high- and low-affinity forms of CCR5 less than 
D1/85.16, the resistant virus with three FP substitutions [127]. 
Although derived from a common parent, CC1/85, two resistant viruses that we have 
described, CC101.19 and D1/85.16, followed different genetic pathways to reach the same 
phenotypic endpoint: CC101.19 acquired four substitutions (K305R, H308P, A316V and 
G321E) in the V3 region [107], while the key determinants of resistance in D1/85.16 were 
three changes in the gp41 FP (G516V, M518V and F519I) [126] (Table 2). Both resistant 
variants acquired the ability to use the VCV–CCR5 complex for entry [107, 108, 126, 142].  
However, unlike a clone derived from CC101.19 (V3 mutations), the D1/85.16 cl.23 virus (FP 
mutations) did not have an increased dependency on the CCR5 Nt, and its CCR5 binding 
site was not obviously more exposed [144]. The FP-mutant was, however, atypically 
sensitive to a CCR5 MAb that stains discrete cell surface clusters of CCR5 that might 
correspond to lipid rafts [145]. The precise molecular mechanism by which the FP changes 
confer resistance remains to be determined. 
The V3 changes that confer resistance to CCR5 inhibitors have been suggested to render the 
virus more dependent on the CCR5 Nt, to compensate for impaired interactions between the 
V3-crown and ECL2 [144]. Accordingly, substantial deletions in V3 from both HIV-1 and 
HIV-2 confer complete resistance to coreceptor antagonists, presumably by disrupting the 
interaction between V3 and ECL2 [146-150]. Any adverse effect the V3 sequence changes 
have at the CCR5-binding stage may be compensated for by increases in the affinity of 
resistant viruses for CD4 and/or in the kinetics of virus entry [147, 151]. The altered virus–
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CCR5 interactions are nonetheless characterized by considerable complexity. Thus, a 
subtype D, VCV-resistant patient isolate recognizes the drug-bound form of CCR5 more 
efficiently but still uses both the Nt and ECL2 [123]. A recently proposed model suggests 
that broad cross-resistance to multiple inhibitors is associated with an increased dependence 
on the N-terminus, while a more specific pattern of resistance to individual compounds 
involves more subtle changes in how the virus interacts with both the Nt and ECL2 [129]. 
5.3. In vivo resistance: Potential expansion of pre-existing, CXCR4-using viruses 
The limited information currently available from published results of clinical studies 
suggests that the escape process from small molecule CCR5 inhibitors in vivo bears 
similarities to that observed in vitro; clinical resistance is also likely to map to the V3 region 
of gp120, but the lack of consistency of observed mutations renders impossible the 
prediction of in vivo resistance by sequence analysis at present (reviewed in [72, 77, 117, 141]). 
As mentioned above, two pathways of virological escape from the selection pressure of CCR5 
antagonists have been identified: continued use of CCR5 via selection of R5 virus that can use 
drug-bound CCR5 for entry in addition to free coreceptor and expansion of pre-existing 
minority populations of dual-tropic or X4 virus (collectively called “CXCR4-using” viruses). 
The first pathway of R5 virological failure with reduced susceptibility to CCR5 antagonists is 
not the most common mechanism of failure. Virologic failure most commonly involves 
expansion of pre-existing, CXCR4-using viruses that are insensitive to CCR5 inhibitors. This 
outcome underscores the importance of developing tropism assays with improved ability to 
detect minor or archived virus populations capable of using the CXCR4 coreceptor. 
The Trofile assay has been the assay of choice for clinical trials of CCR5 inhibitors. However, 
the sensitivity of the original commercially available assay was compromised with respect 
to the detection of low abundance (minority) CXCR4-using variants. As a result, a number 
of subjects were misjudged to have R5 virus at screening, whereas they actually harbored 
Dual/Mixed (D/M) virus populations when they entered clinical trials of CCR5 inhibitors; 
these patients appeared to have a blunted virologic response and high rates of early 
virologic failure [152-154]. Application of an enhanced-sensitivity Trofile assay or “deep 
sequencing” and re-analysis of the data showed that virologic failure in a significant 
proportion of these patients stemmed from the expansion of pre-existing minority CXCR4-
using variants that went undetected during the first round of testing [155-157]. Accurate 
determination of coreceptor usage is therefore necessary to optimize treatment strategies 
before the initiation of and during therapy with CCR5 inhibitors. Techniques such as deep 
V3 sequencing may be useful for identifying treatment-experienced individuals who could 
benefit from CCR5-antagonist-containing regimens [158]. Ongoing improvements in 
genotypic methodologies and algorithms may eventually render them a viable alternative to 
phenotypic assays, much like the genotypic resistance methods. 
6. Conclusions and future directions 
The identification of CCR5 as the principal HIV coreceptor for cellular entry over a decade 
ago combined with the observed effects of the CCR5∆32 polymorphism (natural resistance 
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to HIV infection in homozygotes and delayed disease progression in heterozygotes) in the 
absence of any overt pathology, sparked great interest in its pharmaceutical blockade. The 
orally bioavailable small molecule CCR5 inhibitors are perhaps the most promising drugs 
that have been developed to block CCR5. In 2007, Maraviroc (MVC) became the first 
member of this new class of antiretrovirals, which target host- rather than virus-encoded 
structures, to receive regulatory approval for clinical use in the treatment of HIV infection. 
The theoretical virological concern that use of CCR5 antagonists in therapy may accelerate 
the evolution towards the more pathogenic CXCR4-using viruses has not been observed in 
clinical studies to date. MVC and other CCR5 antagonists have the potential for use in a 
variety of other clinical situations, such as the prevention of HIV transmission, 
intensification of HIV treatment and prevention of rejection in organ transplantation 
(reviewed in [159]). Moreover, CCR5 antagonists may be used in combination with other 
entry inhibitors or with agents such as rapamycin which downregulates CCR5 receptors 
thus decreasing CCR5 density [159]. New drugs that promote CCR5 and CXCR4 
internalization, independent of cellular signaling, might also provide clinical benefits with 
minimum side effects [13]. 
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